首页>
外国专利>
BIOMARKERS AND PARAMETERS FOR HYPERTENSIVE DISORDERS DURING PREGNANCY
BIOMARKERS AND PARAMETERS FOR HYPERTENSIVE DISORDERS DURING PREGNANCY
展开▼
机译：妊娠期高血压疾病的生物标记和参数
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: biotechnology.;SUBSTANCE: invention relates to biomarkers and parameters used to predict preeclampsia. Method for predicting preeclampsia in a subject includes measuring blood pressure (BP) in a subject at about 15 weeks gestation; measuring, in a sample taken from a subject, the level of placental growth factor (PIGF), the level of the acid-resistant subunit of the complex protein that binds to insulin-like growth factor (IGFALS); the level of multimerin-2 (MMRN2), the level of cell surface glycoprotein MUC18 (MCAM), the level of disintegrin and protein containing the metalloproteinase domain 12 (ADAM12); comparing biomarker levels and blood pressure values with standard values obtained at the same gestational age in subjects who do not have the corresponding disease or risk of developing such a disease; detection of deviations or absence of deviations of biomarker levels and blood pressure values compared with standard values; prediction of PE in the subject based on said deviation or absence of deviation.;EFFECT: invention is characterised by high sensitivity and specificity of prediction of preeclampsia, and also has a high predictive value both in the early and late period of development of preeclampsia.;1 cl, 1 dwg, 14 tbl, 14 ex
展开▼
机译：技术领域本发明涉及用于预测先兆子痫的生物标志物和参数。预测受试者的先兆子痫的方法包括在妊娠约15周时测量受试者的血压（BP）。在取自受试者的样品中，测量胎盘生长因子（PIGF）的水平，即与胰岛素样生长因子（IGFALS）结合的复合蛋白的耐酸亚基的水平; multimerin-2（MMRN2）的水平，细胞表面糖蛋白MUC18（MCAM）的水平，双整合素和含有金属蛋白酶结构域12的蛋白（ADAM12）的水平;将没有发生相应疾病或罹患这种疾病风险的受试者的生物标志物水平和血压值与在同一胎龄下获得的标准值进行比较;检测生物标志物水平和血压值与标准值之间是否存在偏差;效果：本发明的特征在于对先兆子痫的预测具有很高的敏感性和特异性，并且在先兆子痫的发展的早期和晚期都具有很高的预测价值。 ; 1 cl，1 dwg，14 tbl，14 ex
展开▼
